H.R. 2679 118th Congress
Pharmacy Benefits Manager Accountability Act
- Health
- Sponsor: Rep. Kuster, Ann M. [D-NH-2]
- Congress.gov ↗
Latest action, Dec 17, 2024: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
5 cosponsors
Sponsored by Rep. Kuster, Ann M. [D-NH-2] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
3 D · 2 R
Referred to: House: Education and Workforce Committee; House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
AMGEN USA INC.
MARSHALL & POPP, LLC
7 reports
7 reports
GENENTECH, INC.
MARSHALL & POPP, LLC
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
PFIZER, INC.
MARSHALL & POPP, LLC
7 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
MARSHALL & POPP, LLC
7 reports
SANOFI U.S. SERVICES, INC.
MARSHALL & POPP, LLC
7 reports
THE BIOSIMILARS FORUM
THORN RUN PARTNERS
7 reports
All 25 of 29 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICAN COLLEGE OF RHEUMATOLOGY | 7 | $670K | Q4 2023 | Q3 2024 | yes | |
| AMGEN USA INC. | MARSHALL & POPP, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| CVS HEALTH (AND SUBSIDIARIES) | 7 | $14.0M | Q4 2023 | Q3 2024 | yes | |
| GENENTECH, INC. | MARSHALL & POPP, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.2M | Q4 2023 | Q3 2024 | yes | |
| HIGHMARK INC | 7 | $1.3M | Q4 2023 | Q3 2024 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 7 | $4.4M | Q4 2023 | Q3 2024 | yes | |
| MERCK & CO INC | 7 | $16.2M | Q4 2023 | Q3 2024 | yes | |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 7 | $2.5M | Q4 2023 | Q3 2024 | yes | |
| NOVARTIS | 7 | $9.2M | Q4 2023 | Q3 2024 | yes | |
| PFIZER, INC. | MARSHALL & POPP, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $50.1M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | MARSHALL & POPP, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| SANOFI U.S. SERVICES, INC. | MARSHALL & POPP, LLC | 7 | $420K | Q4 2023 | Q3 2024 | yes |
| THE BIOSIMILARS FORUM | THORN RUN PARTNERS | 7 | $710K | Q4 2023 | Q3 2024 | yes |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | 7 | $13.5M | Q4 2023 | Q3 2024 | yes | |
| AMGEN INC | 6 | $18.1M | Q4 2023 | Q3 2024 | yes | |
| TAKEDA PHARMACEUTICALS AMERICA INC | 5 | $4.6M | Q4 2023 | Q3 2024 | yes | |
| AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 4 | $940K | Q2 2023 | Q3 2024 | yes | |
| FOOD MARKETPLACE INC | 4 | $1.5M | Q4 2023 | Q1 2024 | yes | |
| CIGNA CORPORATION | INVARIANT LLC | 3 | $270K | Q4 2023 | Q1 2024 | yes |
| INFUSION PROVIDERS ALLIANCE | 3 | $81K | Q1 2023 | Q3 2023 | yes | |
| OCHSNER CLINIC FOUNDATION | 3 | $550K | Q4 2023 | Q3 2023 | yes | |
| PLANNED PARENTHOOD FEDERATION OF AMERICA INC | 2 | $510K | Q2 2023 | Q3 2023 | yes | |
| ELEVANCE HEALTH, INC. | 1 | $1.4M | Q2 2023 | Q2 2023 | yes |